Six monthly and 3 monthly paliperidone palmitate injection equally effective for preventing relapse in schizophrenia
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-05-11 03:00 GMT | Update On 2023-05-11 07:39 GMT
Advertisement
A team of researchers led by Dr Cesar Giron-Hernandez examined the efficacy and safety of paliperidone palmitate (PP) 6-month (PP6M) vs PP3-month (PP3M) long-acting injectable (LAI) in schizophrenia patients from European sites previously stabilized on PP3M or PP1-month (PP1M).
The study is published in Neuropsychiatric Disease and Treatment.
They concluded that PP6M efficacy was non-inferior to PP3M in preventing relapse in the European subgroup previously treated with PP1M or PP3M (consistent with the global study). They did not report any new safety signals in the study.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.